ATXI

Avenue Therapeutics, Inc. [ATXI] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ATXI Stock Summary

In the News

ATXI Financial details

Company Rating
-
Market Cap
6M
Income
-11.55M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-0.09
Forward P/E
-
PEG
0
P/S
-
P/B
-0.17
P/C
-
P/FCF
-0.2
Quick Ratio
0.03
Current Ratio
0.1
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2
EPS next Y
-
EPS next Q
-
EPS this Y
-204.26%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-61.42%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-1429%
ROE
439%
ROC
3.61%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.113-1.28
52W High
-
52W Low
-
RSI
49
Rel Volume
-
Avg Volume
1.68M
Volume
14
Perf Week
-7.4%
Perf Month
-5.9%
Perf Quarter
204.34%
Perf Half Y
210.98%
-
-
-
-
Beta
-0.26
-
-
Volatility
0%, 0.06%
Prev Close
0%
Price
0.7152
Change
0.72%

Something similar

Top by Market Cap
VOO
3V64.DE
APC.DE
1YD.DE
VTI
Same Sector
PAVMZ
HTGM
ONT.L
SCIB.ST
AXNX
Same Price Range
6811.HK
CCTC
0620.HK
KPG.NZ
3816.HK
Similar Market Cap
DFU.TO
CNPIX
MHPC
IRVH
ALESA.PA

Company Profile

Healthcare Biotechnology
  • Volume Average 1.68M
  • Market Capitalization 6M
  • Employee 3
  • CEO Dr. Alexandra MacLean M.D.
  • Headquarters New York,NY,US
  • IPO Date 2017-06-27
  • Website https://www.avenuetx.com

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.